FDA reports new deaths with diabetes drug Byetta

Aug 18, 2008 By MATTHEW PERRONE , AP Business Writer

(AP) -- Federal regulators are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after deaths continue to be reported despite earlier government warnings.



Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .

Explore further: US appeals court upholds delay in Alzheimer's drug swap

Related Stories

Designing better medical implants

May 18, 2015

Biomedical devices that can be implanted in the body for drug delivery, tissue engineering, or sensing can help improve treatment for many diseases. However, such devices are often susceptible to attack by ...

Wireless sensor transmits tumor pressure

Sep 20, 2014

The interstitial pressure inside a tumor is often remarkably high compared to normal tissues and is thought to impede the delivery of chemotherapeutic agents as well as decrease the effectiveness of radiation ...

Short nanotubes target pancreatic cancer

Jun 05, 2014

(Phys.org) —Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice University and the University ...

Functional nerve cells from skin cells

May 21, 2014

A new method of generating mature nerve cells from skin cells could greatly enhance understanding of neurodegenerative diseases, and could accelerate the development of new drugs and stem cell-based regenerative ...

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Sepp
5 / 5 (1) Aug 18, 2008
Pretty bad when a drug for a condition that can be controlled by dietary means causes people to die of pancreatitis. What does the FDA? Require a warning.

In contrast, when a natural nutrient product causes similar trouble, the answer is usually to ban that product outright.

Double standard?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.